Tedisamil

Drug Profile

Tedisamil

Alternative Names: KC-8857

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Solvay
  • Class Class III antiarrhythmics; Cyclopropanes; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atrial fibrillation; Atrial flutter
  • Discontinued Angina pectoris; Ischaemic heart disorders

Most Recent Events

  • 15 Jun 2015 No recent reports on development identified - Registered for Atrial fibrillation in Spain and United Kingdom (IV)
  • 15 Jun 2015 No recent reports on development identified - Registered for Atrial flutter in Spain and United Kingdom (IV)
  • 26 Mar 2009 Tedisamil is available for licensing in Europe (http://www.solvay.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top